APA (7th ed.) Citation

Cottu, P., De Laurentiis, M., Marchetti, P., Coltelli, L., Califaretti, N., Debled, M., . . . Salvador Bofill, J. (2019). 333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial. Annals of Oncology, 30, v118. https://doi.org/10.1093/annonc/mdz242.028

Chicago Style (17th ed.) Citation

Cottu, P.H, et al. "333P - Ribociclib (RIB) + Letrozole (LET) in Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor-2–negative (HER2–) Advanced Breast Cancer (ABC) and Central Nervous System (CNS) Metastases: Subgroup Analysis from the Phase IIIb CompLEEment-1 Trial." Annals of Oncology 30 (2019): v118. https://doi.org/10.1093/annonc/mdz242.028.

MLA (9th ed.) Citation

Cottu, P.H, et al. "333P - Ribociclib (RIB) + Letrozole (LET) in Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor-2–negative (HER2–) Advanced Breast Cancer (ABC) and Central Nervous System (CNS) Metastases: Subgroup Analysis from the Phase IIIb CompLEEment-1 Trial." Annals of Oncology, vol. 30, 2019, p. v118, https://doi.org/10.1093/annonc/mdz242.028.